Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

U.S. pharma giant Eli Lilly And Co (NYSE:LLY) announced the launch of its popular weight loss drug Mounjaro (tirzepatide) in ...

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising ...

(Reuters) -Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest ...

In a detailed feature by TIME Magazine, pharmaceutical giant Eli Lilly has unveiled promising early results from clinical ...